AVR vs EW
AVR: Anteris Technologies is a medical technology firm developing innovative, next-generation structural heart valve replacement therapies. EW: Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring.
Side-by-side fundamentals
| Metric | AVR | EW | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $6.63 | $84.24 | |
| Market cap | $646M | $48.6B | |
| P/E as of 2026-10-08 | n/a | 48.74 | |
| Net margin FY2025, SEC XBRL | -4921.3% | +17.7% | EW higher |
| Gross margin FY2025, SEC XBRL | n/a | +78.0% | |
| Operating margin FY2025, SEC XBRL | -4908.2% | +20.8% | EW higher |
| ROE FY2025, SEC XBRL | n/a | +10.4% | |
| ROA FY2025, SEC XBRL | -409.4% | +7.8% | EW higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.06 | AVR lower |
| Revenue growth (YoY) as of 2026-09-03 | -0.5% | +14.6% | EW higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +10.8% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.66 | 0.55 | |
| 1-year return as of 2026-10-08 close | +38.7% | +11.2% | AVR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.